Disclosure of total number of voting rights and number of shares in the capital as of February 28th, 2023

We transform medical images into meaningful, actionable insights to help better diagnose, treat, and monitor patients. We deploy proprietary artificial intelligence, computer vision, and signal processing technologies to develop imaging tests and services, addressing life-threatening unmet medical needs.

With eyonis® we are disrupting the management of serious diseases such as lung cancer and liver cancer. We are deploying AI/ML Software as Medical Devices (SaMDs) to help health professionals diagnose patients earlier, treat them more effectively, and bring new hope. eyonis® is currently under development.

Imaging Services for Clinical Trials

Median’s Imaging CRO business provides leading oncology clinical trial imaging services, empowering our life sciences partners to accelerate the development and delivery of life-saving cancer treatments with unmatched operational excellence and reliability. And we don’t stop there. We are forging the way when it comes to innovative imaging technology, leveraging the latest in AI-powered imaging intelligence to develop actionable insights for biopharma sponsors worldwide.

Learn More

Request a Demo

Press Release – For immediate release – 5:45 pm CET

Disclosure of total number of voting rights and number of shares in the capital as of February 28^th, 2023, pursuant to article L-223-8 II of the French “code de Commerce” and 223-16 of the AMF’s General Regulations.

Total number of shares	15,801,449
Number of real voting rights* (excluding treasury shares**)	15,753,674
Theoretical number of voting rights* (including treasury shares**)	15,778,249

(*) Class E preference shares are non-voting

(**) Pursuant to article 223-&& of the AMF’s General Regulations

Back to press releases